Literature DB >> 14628985

How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial?

Gabor I Keitner1, Michael A Posternak, Christine E Ryan.   

Abstract

OBJECTIVE: To evaluate the generalizability of the results of antidepressant efficacy trials by determining how many subjects with DSM-IV major depressive disorder who apply for entry into such trials are ultimately enrolled.
METHOD: The screening results of 378 subjects who inquired about participating in 1 of 2 separate antidepressant efficacy trials performed at Rhode Island Hospital between 1997 and 2002 were reviewed. The number of subjects who enrolled, as well as the reasons for exclusion of those who did not meet eligibility requirements, were determined.
RESULTS: Of the 378 inquiries, 186 subjects expressed interest and received a current major depressive disorder diagnosis. From this sample, 27 (14.5%) were ultimately enrolled in 1 of the 2 antidepressant trials. The most common reasons for exclusion were bipolar disorder (17.2%), drug or alcohol abuse (15.6%), mild depression (14.0%), medical contraindication (12.9%), and the use of prohibited psychotropic medications (12.4%).
CONCLUSION: The majority of subjects with major depressive disorder who apply to participate in an antidepressant efficacy trial do not meet eligibility requirements. When prescribing antidepressants, clinicians should bear in mind that the results of these trials may only be directly applicable to a small subset of patients treated in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14628985     DOI: 10.4088/jcp.v64n0915

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

Review 1.  Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

Authors:  Mark Zimmerman; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian; Heather L Clark
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

2.  Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication.

Authors:  Rebecca C Didham; Doug W McConnell; Hayden J Blair; David M Reith
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

3.  Methodological issues in conducting treatment trials for psychological nonepileptic seizures.

Authors:  W Curt LaFrance; Andrew S Blum; Ivan W Miller; Christine E Ryan; Gabor I Keitner
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

4.  Personalized prognostic prediction of treatment outcome for depressed patients in a naturalistic psychiatric hospital setting: A comparison of machine learning approaches.

Authors:  Christian A Webb; Zachary D Cohen; Courtney Beard; Marie Forgeard; Andrew D Peckham; Thröstur Björgvinsson
Journal:  J Consult Clin Psychol       Date:  2020-01

5.  Antidepressants and risks of suicide and suicide attempts: a 27-year observational study.

Authors:  Andrew C Leon; David A Solomon; Chunshan Li; Jess G Fiedorowicz; W H Coryell; Jean Endicott; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2011-05       Impact factor: 4.384

6.  Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures.

Authors:  W C LaFrance; G I Keitner; G D Papandonatos; A S Blum; J T Machan; C E Ryan; I W Miller
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

7.  Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

Authors:  Sana M Al-Khatib; Anne Hellkamp; Gust H Bardy; Stephen Hammill; W Jackson Hall; Daniel B Mark; Kevin J Anstrom; Jeptha Curtis; Hussein Al-Khalidi; Lesley H Curtis; Paul Heidenreich; Eric D Peterson; Gillian Sanders; Nancy Clapp-Channing; Kerry L Lee; Arthur J Moss
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

8.  "Caseness" for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories.

Authors:  Koen Demyttenaere; Anne Verhaeghen; Nicolas Dantchev; Luigi Grassi; Angel L Montejo; David G S Perahia; Deborah Quail; Catherine Reed; Andre Tylee; Michael Bauer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

9.  The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.

Authors:  Mark Zimmerman; Carolina Guzman Holst; Heather L Clark; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

10.  Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder.

Authors:  David E Kemp; Keming Gao; Elizabeth B Fein; Philip K Chan; Carla Conroy; Sarah Obral; Stephen J Ganocy; Joseph R Calabrese
Journal:  Bipolar Disord       Date:  2012-11       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.